Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 193, Issue 11, Pages 1589-1597Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/503804
Keywords
-
Categories
Funding
- NIAID NIH HHS [P01 AI037194, R01 AI014209, R01 AI044786, P01 AI037194-080004, R01 AI014209-27, P01 AI37194, R01 AI 44786, R01 AI044786-05] Funding Source: Medline
Ask authors/readers for more resources
Mannan-binding lectin (MBL) is a component of the innate immune system. The goal of the present study was to evaluate binding of MBL to Candida albicans in vitro and in vivo and to assess the impact of MBL treatment on host resistance. The results showed a variable and often discontinuous pattern of binding to individual yeast cells. MBL bound to cells grown at 37 degrees C but not to cells grown at 23 degrees C. The putative MBL ligand was constitutively present on yeast cells grown at 23 degrees C, but the ligand was masked on such cells, such that MBL could not bind. C. albicans yeasts and hyphae in infected tissue bound MBL. Finally, parenteral administration of MBL increased resistance of mice to hematogenously disseminated candidiasis. These results suggest that MBL is an important component of innate resistance to candidiasis and that MBL therapy may be a means to prevent disseminated candidiasis in high-risk patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available